Karin Mayer

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Uwe Platzbecker, Ulrich Germing, Katharina S. Götze et al. · The Lancet Oncology · 2017 · 288 citations

Medicine, Hematology, Pharmacology +8

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

Samer Ezziddin, Feras Khalaf, Maria Vanezi et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 187 citations

Medicine, Nuclear Medicine, Oncology +16

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate

Amir Sabet, Khaled Ezziddin, Ulrich‐Frank Pape et al. · Journal of Nuclear Medicine · 2013 · 167 citations · Full text

Medicine, Nuclear Medicine, Radiation Oncology +17

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i>-mutated AML: results from the AMLSG 09-09 trial

Silke Kapp‐Schwoerer, Daniela Weber, Andrea Corbacioglu et al. · Blood · 2020 · 119 citations · Full text

Medicine, Oncology, Pharmacology +10